BioNTech shuts three German factories as COVID vaccine demand collapses

BioNTech is closing three production sites in Germany, reflecting the post-pandemic collapse in demand for its COVID-19 vaccine. The move signals a strategic pivot away from pandemic-era manufacturing capacity, though the company's broader pipeline and financial health remain uncertain. This is a notable corporate restructuring in the health sector, with implications for regional employment and Germany's biotech manufacturing footprint.